Zymeworks.
company
- Reports this week
- 2
- Active events
- 2
- Connections
- 36
What's happening
Active this week
One to three months ago
Gone quiet
No new reports in 90+ days-
Both Zymeworks and Petros Pharmaceuticals are small-cap medical companies in the biotech sector focusing on men's health therapeutics in the US.Some support1 report
-
The FDA cleared the IND application for ZW251, a product of Zymeworks.Some support4 reports1 development inside
-
Zymeworks achieved FDA approval for its drug zanidatamab, while also announcing personnel and award news.Some support1 report
-
Zymeworks announced a decision from Vancouver.Some support4 reports
-
Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.Some support1 report
-
Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.Some support2 reports
-
Zymeworks shares underperformed the S&P 500 on August 8, 2025.Some support1 report
-
Zymeworks management participated in investor conferences held in Boston on August 19, 2025.Some support2 reports
-
Benzinga provided stock analysis on Zymeworks on September 3, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Zymeworks this week
News at the entities that move Zymeworks most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Zymeworks
-
Jazz Pharmaceuticals StructuralJazz Pharmaceuticals plans U.S. launch of Ziihera.Moves Zymeworks
-
Johnson & Johnson StructuralP&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Moves Zymeworks
-
Ireland StructuralIreland is working to improve governmental transparency by enhancing its digital services.Moves Zymeworks
-
Truist Financial Mentioned togetherMarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.Moves Zymeworks
-
OMERS TransactionalPension fund leadership, including Mark Carney, responds to government investment pushes regarding the operations of OMERS.Moves Zymeworks
Connections
The 15 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Paul Moore Structural
Paul Moore holds the formal position of Chief Scientific Officer at Zymeworks.
-
FDA Structural
FDA formally regulates Zymeworks, granting product approvals and clearing necessary applications.
-
Johnson & Johnson Structural
J&J relies on Zymeworks' proprietary technology platform for the development and production of pasritamig.
-
Jazz Pharmaceuticals Structural
A strategic partnership exists where Jazz utilizes Zymeworks' technology platform, with financial milestones and royalties tied to A's regulatory successes.
-
Nasdaq Structural
Zymeworks is a company publicly listed and trades on the Nasdaq stock exchange.
-
OMERS Transactional
OMERS subscribed to a non-recourse note related to Zymeworks.
-
Mylan Operational
The evidence suggests a functional partnership where Zymeworks leverages market access provided by the entity currently operating under the Viatris umbrella, which is the operational successor to Mylan.
-
Boston Shared context
Zymeworks holds investor meetings and participates in conferences within the city of Boston.
Show all 15 connections
-
Ireland Structural
Zymeworks leverages Ireland's fiscal environment by utilizing its tax attributes.
-
New York Shared context
Zymeworks is scheduled to hold investor meetings in the geographic area of New York.
-
Chicago Shared context
Zymeworks participates in scientific meetings held in Chicago.
-
Truist Financial Mentioned together
Truist Financial raised its price target on Zymeworks, signaling market confidence in the company.
-
Vancouver Shared context
Zymeworks is headquartered and conducts its operations from Vancouver, Canada.
-
MarketBeat Mentioned together
MarketBeat aggregates data on Zymeworks as part of its function as a financial news hub.
-
Jason McCarthy Mentioned together
No relationship between Zymeworks and Jason McCarthy was observed in the provided evidence.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
1 eventJuly 2026
2 eventsShow 1 earlier month
June 2026
10 events- Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.
- Both Zymeworks and Petros Pharmaceuticals are small-cap medical companies in the biotech sector focusing on men's health therapeutics in the US.
- The FDA cleared the IND application for ZW251, a product of Zymeworks.
- Zymeworks achieved FDA approval for its drug zanidatamab, while also announcing personnel and award news.
- Zymeworks announced a decision from Vancouver.
- Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.
- Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.
- Zymeworks shares underperformed the S&P 500 on August 8, 2025.
- Zymeworks management participated in investor conferences held in Boston on August 19, 2025.
- Benzinga provided stock analysis on Zymeworks on September 3, 2025.